Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.

The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for its gout drug, dotinurad.

Evogene and ELEO have entered into a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the PCSK9 pathway for hyperlipidemia and cardiovascular ...

Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugma ...

UK biotech financing recovery was present in the private markets in Q2 2026 as the sector contends with a tough global funding landscape.

Cellares and Papillon Therapeutics have entered into a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the latter for FA, a rare inherited ...

If introduced, the 100% tariffs would apply to all generic drugs imported to the US, which make up 90% of the nation’s prescriptions.

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

BMS enhances its AI computing power with NVIDIA's DGX SuperPOD as big pharma race to stay competitive within the shifting global landscape.

Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.

In a lawsuit filed in the US, Novo alleged that Lilly’s campaign was designed to mislead consumers on “comparative efficacy” of drug brands.

The EMA’s CHMP has granted PRIME designation to AbelZeta Pharma’s C-CAR168, an autologous anti-CD20/BCMA CAR-T therapy.